HK Stock Market Move | TYK MEDICINE-B (02410) rose by more than 34% during trading, its core product is undergoing clinical trials, institutions believe it has strong competitive advantages.

TYK Medicines-B (02410) rose by more than 34% during trading hours, reaching a 28.43% increase at the time of writing, with a price of 25.3 Hong Kong dollars and a trading volume of 1.0544 million Hong Kong dollars. It is reported that TYK Medicines is a clinical-stage biopharmaceutical company, whose core business model includes internal discovery, development, and commercialization of small molecule drugs and other innovative drug types (such as PROTAC) to address unmet needs in the field of cancer, especially in lung cancer. The company has established a pipeline consisting of 11 candidate drugs, including 2 low-risk products TY-9591 (core product) and TY-302 (key product), 5 innovative clinical products, and 4 products in the preclinical stage. The company is currently conducting a Phase II clinical trial of TY-9591 monotherapy in China, using it for first-line treatment of brain metastasis in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, as well as a Phase III clinical trial for registration of TY-9591 monotherapy in China, using it for first-line treatment of locally advanced (Stage IIIb or IV) or metastatic NSCLC with EGFRL858R mutation. Guoyuan International previously pointed out that the company has significant innovation in the treatment of brain metastasis in small cell lung cancer, giving it a strong competitive advantage.